On December 18th, Eli Lilly announced that its Alzheimer's disease therapy, Genentech&Co., Ltd; reg; Duonai monoclonal antibody injection has been registered and approved by the National Medical Products Administration as a Class 1 innovative drug for the treatment of mild cognitive impairment and mild dementia caused by Alzheimer's disease in adults. After the United States, Japan, and the United Kingdom, China has approved the use of Minolta; reg; Another major market for listing.
Li Lai introduced that Ji Nengda& reg; It is the only targeted amyloid therapy with evidence supporting discontinuation after clearing amyloid plaques, which can help patients reduce treatment burden by reducing infusion frequency and treatment costs. It is reported that the product is a prescription drug that is administered intravenously every four weeks. The first three doses are 700 milligrams, followed by 1400 milligrams.
According to a key Phase 3 study, compared to placebo, JiNengda& reg; Reduced cognitive and functional decline by up to 35%. At the same time, for subjects with earlier stages of the disease, JiNengda& reg; Reduced the risk of disease progression by up to 39% within 18 months.